Library — CHDR

Search

Filter

Pharmacokinetics and pharmacodynamics of oral mecamylamine - development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation.

Alvarez-Jimenez R, Baakman AC, Stevens J, Goulooze SC, Hart EP, Rissmann R, van Gerven JM, Groeneveld GJ

Journal of psychopharmacology (Oxford, England), 2018 Feb; 31(2):192-203

View publication
An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine.

Baakman AC, Alvarez-Jimenez R, Rissmann R, Klaassen ES, Stevens J, Goulooze SC, den Burger JCG, Swart EL, van Gerven JMA, Groeneveld GJ

British journal of clinical pharmacology, 2018 Feb; 83(8):1676-1687

View publication
Serotonergic and cholinergic modulation of functional brain connectivity: A comparison between young and older adults.

Klaassens BL, van Gerven JMA, Klaassen ES, van der Grond J, Rombouts SARB

NeuroImage, 2018 Feb

View publication
The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study.

van de Loo AJAE, Bervoets AC, Mooren L, Bouwmeester NH, Garssen J, Zuiker R, van Amerongen G, van Gerven J, Singh J, der Ark PV, Fedgchin M, Morrison R, Wajs E, Verster JC

Psychopharmacology, 2017 Nov; 234(21):3175-3183

View publication
Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects.

Alvarez-Jimenez R, Groeneveld GJ, van Gerven JM, Goulooze SC, Baakman AC, Hay JL, Stevens J

British journal of clinical pharmacology, 2016 Sep; 82(4):1011-21

View publication
Reliability of System Identification Techniques to Assess Standing Balance in Healthy Elderly.

Pasma JH, Engelhart D, Maier AB, Aarts RG, van Gerven JM, Arendzen JH, Schouten AC, Meskers CG, van der Kooij H

PloS one, 2016 Apr; 11(3):e0151012

View publication
Pharmacokinetic/pharmaco-dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ(9)-tetrahydrocannabinol challenge tests.

Guan Z, Klumpers LE, Oyetayo OO, Heuberger J, van Gerven JM, Stevens J

British journal of clinical pharmacology, 2016 Mar; 81(4):713-23

View publication
The use of biomarkers in human pharmacology (Phase I) studies.

Cohen AF, Burggraaf J, van Gerven JM, Moerland M, Groeneveld GJ

Annual review of pharmacology and toxicology, 2015 Apr

View publication
Lessons Learned and Potentials for Improvement in CNS Drug Development: ISCTM Section on Designing the Right Series of Experiments.

Szabo ST, Kinon BJ, Brannan SK, Krystal AK, van Gerven JM, Mahableshwarkar A, Sachs GS

Innovations in clinical neuroscience, 2015 Apr; 12(3-4):11S-25S

View publication

«
1
2
3
4
5
6
»